Braidwell LP Merus N.V. Transaction History

Braidwell LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $30.7 Million - $43.9 Million	-1,530,658 Reduced 80.5%	370,679 $10.2 Billion
Q3 2023 Nov 14, 2023	BUY	$20.13 - $27.29 $7.21 Million - $9.77 Million	358,175 Added 23.21%	1,901,337 $0
Q2 2023 Aug 14, 2023	BUY	$18.33 - $27.18 $1.28 Million - $1.9 Million	70,078 Added 4.76%	1,543,162 $40.6 Billion
Q1 2023 May 15, 2023	SELL	$14.25 - $20.5 $7.48 Million - $10.8 Million	-525,000 Reduced 26.28%	1,473,084 $27.1 Billion
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $25.6 Million - $47.3 Million	1,998,084 New	1,998,084 $30.9 Billion

200

62M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.88B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

Stay updated on Braidwell LP with notifications on news.